Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US OK for GSK meningococcal vaccine protects babies, without added shots

This article was originally published in Scrip

Executive Summary

When GlaxoSmithKline set out to develop a vaccine to protect young infants from meningococcal disease caused by Neisseria meningitidis, which is rare, but deadly, the company wanted to ensure it was not burdening immunization delivery for those patients – with babies' schedule for shots already "crowded," said Dr Leonard Friedland, North American vice president of clinical and medical affairs at the firm's vaccine unit.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts